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PKB/AKTCell cycle progression through its regulatory control by changes in intracellular Ca2+ levels at the G1/S
transition mediates cellular proliferation and viability. Ca2+/CaM-dependent kinase 1 (CaMKI) appears
critical in regulating the assembly of the cyclin D1/cdk4 complex essential for G1 progression, but how this
occurs is unknown. Cyclin D1/cdk4 assembly in the early G1 phase is also regulated via binding to p27.
Here, we show that a ubiquitin E3 ligase component, F-box protein Fbxl12, mediates CaMKI degradation
via a proteasome-directed pathway leading to disruption of cyclin D1/cdk4 complex assembly and resultant
G1 arrest in lung epithelia. We also demonstrate that i) CaMKI phosphorylates p27 at Thr157 and Thr198 in
human cells and at Thr170 and Thr197 in mouse cells to modulate its subcellular localization; ii) Fbxl12-
induced CaMKI degradation attenuates p27 phosphorylation at these sites in early G1 and iii) activation of
CaMKI during G1 transition followed by p27 phosphorylation appears to be upstream to other p27 phosphor-
ylation events, an effect abrogated by Fbxl12 overexpression. Lastly, known inducers of G1 arrest signiﬁcantly
increase Fbxl12 levels in cells. Thus, Fbxl12 may be a previously uncharacterized, functional growth inhibitor
regulating cell cycle progression that might be used for mechanism-based therapy.
© 2013 The Authors. Published by Elsevier Inc. Open access under CC BY license. 1. Introduction
During cell replication, the G1 phase is critical and regulated by inte-
gration of a variety of signals that determine whether the cell is des-
tined to proliferate, differentiate, or die [1]. Thus, G1 progression and
transition to the next phase is most essential in cell fate. The control
of factors that mediate G1 phase transition are regulated partly by the
Skp–cullin–F box (SCF) ubiquitin-ligase complexes that typically bind
to phosphorylated substrates to mediate their ubiquitination and deg-
radation [2]. F-box proteins contain two domains: an NH2-terminal
F-box motif and carboxyl-terminal leucine-rich repeat (LRR) motif or
WD repeat motif. The F-box motif binds Skip1, whereas LRR/WD is
used for substrate recognition. The SCF complexes have emerged as
important modulators of cell cycle progression in normal, transformed,
or malignant cells via degradation of key regulatory proteins such as
G1-phase cyclins, cyclin dependent kinase (cdk) inhibitors, transcrip-
tion factors and others. In this SCF complex, the F box protein confersburgh, Pulmonary, Allergy &
op St., Pittsburgh, PA 15213,
.
andian).
nc. Open access under CC BY license. substrate recognition speciﬁcity. Recently, the F-box protein, Fbxo31,
was shown to initiate G1 arrest via cyclin D1 degradation after DNA
damage caused by γ-irradiation [3]. Another related protein, Fbxl12,
mediates osteoblast cell differentiation by mediating p57kip2 ubiquitin-
proteasome degradation [4]. Unlike other SCF F-box proteins that usu-
ally target phosphodegrons, the recently described Fbxl2 protein targets
cyclin D2 [5] or cyclin D3 [6] via recognition of a canonical calmodulin
(CaM)-binding motif that induces Go or G2/M arrest respectively.
Calcium (Ca2+) is a second messenger that is universally required
for cell proliferation that via its ubiquitous intracellular receptor, CaM,
activates calcium/calmodulin-dependent protein kinase (CaMK) cas-
cades required for cell cycle transition. Eukaryotic cells are extremely
sensitive to changes in intra and extracellular levels of calcium. For
example, the lowering of extracellular Ca2+ decreases the rate of cell
proliferation and causes G1 arrest where early G1 and G1/S checkpoints
are the most sensitive to Ca2+ depletion during cell cycle progression
[7,8]. The intracellular Ca2+ pool is also important as depletion of
Ca2+ from intracellular stores induces accumulation of cells in a quies-
cent state [9].
Ca2+/CaM-dependent kinases that comprise the CaMK family
are involved in every stage of the cell cycle and are especially im-
portant for cell cycle entry and G1/S transition [10]. The activation
of Ca2+/CaM-dependent kinase 1 (CaMKI) belonging to this family
is dependent on Ca2+/CaM binding and phosphorylation by the up-
stream Ca2+/CaM-dependent kinase kinase (CaMKK) for maximal
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G1 arrest in a variety of cell types via regulation of cyclin D1 ex-
pression, phosphorylation of the retinoblastoma protein (Rb), and
by prevention of cdk4 activation or by increasing p27 association
with cyclin dependent kinase 2 (cdk2) [14–17]. Recent studies
using KN-93, a CaMKI/II inhibitor, demonstrates that CaMKI regu-
lates cyclin D1/cyclin-dependent kinase 4 (cdk4) complex assem-
bly via an unknown mechanism [18]. Cyclin D1/cdk4 assembly
with p21/p27 results in an inactive complex that accumulates in
the nucleus after KN-93-induced G1 arrest [18]. p27Kip1 is a cyclin-
dependent kinase 4 inhibitor that also facilitates assembly and activa-
tion of cyclin D-cdk(s) complexes in early G1 [19]. Hence, both p27 ac-
tivity and its subcellular localization are critical in regulating G1 phase
transition.
The activity of p27 is controlled by its phosphorylation state,
subcellular localization, and its cellular concentrations and binding
to different cell-cycle regulated complexes [20–23]. For normal cell
cycle progression induced by mitogens, translocation of p27 from
the nucleus to the cytoplasm in G0/early G1 is necessary. This nuclear
export is mediated by the exportin (CRM1) and requires phosphory-
lation of p27 at serine 10 (S10) that can be achieved by actions of
human kinase-interacting stathmin or by the serine/threonine ki-
nases AKT, or CaMKII [23–27]. Phosphorylation of p27 at threonine
157 (T157) by AKT prevents its association with importin α and nu-
clear re-entry during G1 [28]. The other site, threonine 198 (T198)
within p27 which promotes binding to 14-3-3 to facilitate p27 cyto-
plasmic localization is phosphorylated by AKT as well [23]. Recent
studies have demonstrated that phosphorylation of p27 at T157
and T198 by PKB/AKT regulates assembly and activation of the
cyclin D1/cdk4 complex in early G1 [29], whereas phosphorylation
at Thr-187 (T187) leads to proteasomal degradation that can also
occur via direct binding to a ubiquitin E3 ligase independently of
T187 phosphorylation [30–32]. The binding of p27 to cyclin D1/cdk4
via phosphorylation within the p27 cdk interaction domain at tyro-
sine residues also regulates its molecular behavior [33]. In addition,
p27 can serve as a barometer of cellular deregulation of intracellular
signaling and potential predictor of response to targeted therapies
[34]. Thus, p27 is a major regulator of cell cycle progression that via
its reversible phosphorylation modulates cyclin D1/cdk4 complex
formation in early G1. CaMKI also controls cyclin D1/cdk4 complex
assembly, however whether CaMKI exerts its regulatory control of
G1 transition through p27 has not been elucidated.
Here, we demonstrate that the F box protein Fbxl12 mediates
CaMKI proteasomal degradation that causes G1 arrest in lung epithe-
lial cells. Fbxl12 reduces levels of cyclin D1 in the cyclin D1/cdk4
complex by indirectly modulating a new substrate for CaMKI, p27
that is integrally required for cyclin D1/cdk4 complex assembly.
CaMKI phosphorylates human p27 at T157 and T198 and mouse p27
at T170 and T197 to regulate their subcellular localization. Thus, these
data suggest that Fbxl12 is an endogenous CaMKI inhibitor that restricts
cellular proliferation by modulating p27directed cyclin D1/cdk4 com-
plex assembly.
2. Materials and methods
2.1. Materials
MLE and A549 cell lines were obtained from the American Type
Culture Collection (Manassas, VA). Recombinant CaMKI were from
Millipore (Dundee, UK) and Abnova (Taipei City, Taiwan). The TnT
reticulocyte assay system was from Promega (Madison, WI). Talon
metal afﬁnity resin was obtained from Clontech Laboratoties (Valencia,
CA). The Quikchange Site-Direct Mutagenesis kit was from Stratagen
(La Jolla, Ca). FuGENE 6 transfection reagent was purchased from
Roche Diagnostic (Indianapolis, IN). CaMKI and pCaMKI antibody,
Fbxl12 siRNA, CaMKI siRNA and ubiquitin aldehyde were from SantaCruz Biotechnology (Santa Cruz, CA). The p27, cdk4, cdk2, cyclin D1,
cyclin E, Akt, pAkt (T308, S473), ubiquitin (P4D1) and anti-GST Alexa
Fluor 647-conjugated antibodies were purchase from Cell Signaling
(Danvers, MA). Fbxl12 recombinant protein and Fbxl12 antibody
were obtained from Novus Biologicals (Littleton, CO). Anti-Penta-His
Alexa Fluor-conjugated antibody was from QIAGEN (Valencia, CA).
The phosphor-p27/kip1 (T198) antibodywas purchased from R&D sys-
tems (Minneapolis, MN). Ubiquitin was from Enzo (Farmingdale, NY).
The V5 antibody was obtained from Invitrogen (Carlsbad, CA). Anti-
p27 KIP 1 (phosphor S10), anti-p27 KIP 1 (phosphor T157) antibody,
p27 KIP1 GST-tagged protein and active form of CaMKI were purchased
from Abcam (Cambridge, MA). CaMKI shRNA was from OriGene
(Rockville, MD). Myc Tag Antibody was obtained from Aviva Systems
Biology (San Diego, CA). The cell cycle phase determination kit was
obtained from Cayman (Ann Arbor, MI). The GFP-conjugated p27
plasmid (mouse) (15192) was purchased from Addgene (Cambridge,
MA). Pc DNA3 myc3 p27 (human) plasmid was obtained from Addgene
(Cambridge, MA). The Flag-p27, Flag-27T170A, Flag-27T197A and
Flag-p27T170A/T197A plasmids were a kind gift from Cheryl LynWalker
(Department of Carcinogenesis, University of Texas M.D. Anderson
Cancer Center, Houston). Rabbit igG TrueBlot kit was purchased from
eBioscience (San Diego, Ca, USA). Super Signal west Femto kit was
obtained from Thermo Scientiﬁc (Rockford, IL, USA). [γ-32P]-ATP was
from Perkin Elmer Life Science (Waltham, MA, USA). KN-93, MG132
and cycloheximide inhibitors were purchased from Sigma-Aldrich
(St. Louis, MO, USA).2.2. Cell culture
MLE cells were maintained in Hite's medium with 10% fetal bovine
serum at 37 °C. After reaching 80% conﬂuence, the cells were harvested
using trypsin and plated onto 6-well or 100-mm tissue culture dishes.
In some experiments cells were starved by depletion of serum during
24–48 h or exposed to inhibitors. Cell lysates were prepared by brief
sonication in 150 mM NaCl, 50 mM Tris, 1.0 mM EDTA, 2 mM
dithiothreitol, 0.025% sodium azide and 1 mMphenylmethylsulfonyl
ﬂuoride (pH 7.4) at 4 °C.2.3. Immunoblot analysis
Equal amounts of proteins in sample buffer were resolved on
SDS-10% PAGE, transferred to nitrocellulose membranes and then
immunoreactive proteins were detected as described previously
[35]. The dilution factors for majority of antibodies were 1:1000,
for V5 it was 1:5000. Immunoreactive proteins were detected using
a SuperSignal West Femto Substrate reagent.2.4. Immunoprecipitation
Immunoprecipitation was performed with rabbit TrueBlot system
per manufacturer's instructions or using A/G beads. Approximately
200 μg of total proteins were precleared with 30 μl of A/G for 1 h at
4 °C. 3–5 μg of speciﬁc antibody was added for 1–3 h incubation at
4 °C followed by additional incubation with 30 μl of A/G beads.
After incubation beads were spun down and washed 3–5 times with
the buffer containing 50 mM HEPES, 150 mM NaCl, 0.5 mM EGTA,
50 mM NaF, 10 mM Na3VO4, and 1 mM phenymethylsulfonyl ﬂuoride
with 1% [vol/vol] of Triton X-100. The proteins were then released
from the beads by boiling in Laemmli buffer for 5 min, separated by
SDS-PAGE followed by immunoblot analysiswith appropriate antibodies
as described previously [35]. Pull down assays were performed by rota-
tion with V5-, His- and GST-CaMKI beads for 2–4 h at 4 °C. The proteins
were then also released from the beads by boiling in Laemmli buffer for
5 min and processed for SDS-PAG and immunoblot analysis.
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Full length and truncated CaMKI mutants were constructed as
described previously [36]. Brieﬂy, the deletion mutants CaMKI 181,
CaMKI 271, CaMKI 296 and CaMKI K59R and CaMKI K110R, harboring
point mutations were generated by site-direct mutagenesis using simi-
lar PCR-based strategies with appropriate forward and reverse primers,
using His- and V5-double tagged CaMKI plasmid as a template.2.6. Expression of recombinant proteins and siRNA
All plasmids were delivered into the cells by nucleofection using
electroporation instrument AMAXA or transfection using FuGENE6
protocol. Transfections with FuGENE6 were performed in serum-free
medium for 24 h. For siRNA or shRNA studies cells were transfected
with 100 ng of targeted and control RNA using Lipofectamin 2000.
Cells were then harvested after 48 h of incubation.2.7. Immunoﬂuorescence microscopy
MLE cells were cultured on 35 mm MetTek glass-bottom dishes.
Cells were then ﬁxed with 4% of paraformaldehyde for 20 min and
processed for immunocytochemical staining. For detection of endoge-
nous proteins dilutions used for primary antibodies were 1:250–1:500.
Alexa 488 or Alexa 647 was used as secondary antibodies at 1:1000 di-
lutions. The nuclear marker, DAPI was used for visualizing the nuclei.
In some studies cells were transfected with GFP-tagged proteins.
Cell imaging was performed on a Nikon A1 confocal microscope.2.8. In vitro TnT and pull-down assays
For in vitro synthesis, His-tagged CaMKI constructs were added to
the rabbit reticulocyte lysate and incubated with T7 RNA polymerase
in a 50 μl reaction following the manufacturer's instructions. In vitro
synthesized proteins were then processed for pull down with His-
conjugated Talon resin. The His-beads conjugated to CaMKI con-
structs were then washed and used for binding assays.2.9. Cell cycle analysis
Cells transfected with Fbxl12 and LacZ plasmids were incubated
with BrdU (5-bromo-2′-deoxyuridine; 20 mM) for 40 min. MLE
cells were then ﬁxed and stained following the manufacturer's
instructions (BD Biosciences). Fluorescence-activated cells sorter
(FACS) samples were analyzed with the Accuri C6 system. DNA
content was analyzed using FCS3 express software (De NOVO
Software).2.10. In vitro ubiquitin conjugation assays
The ubiquitination of V5-CaMKI was performed in a volume
of 25 μl containing 50 mM Tris pH 7.6, 5 mM MgCl2, 0.6 mM DTT,
2 mM ATP, 1.5 ng/μl E1, 10 ng/μl Ubc5, 10 ng/μl ubiquitin, 1 μM
ubiquitin aldehyde, 4–16 μl of puriﬁed Cullin1, Skp 1, Rbx 1 and
Fbxl12. Reaction products were processed for V5 immunoblotting.2.11. Statistical analysis
Statistical analysis was performed by one-way analysis of variance
or Student's test. Data are presented as mean ± SE.3. Results
3.1. Fbxl12 triggers CaMKI degradation thereby disrupting cyclin D1/cdk4
complex assembly
The molecular control of CaMKI protein stability remains largely
unknown. To assess this, we ﬁrst expressed SCF-based plasmids
encoding F box proteins of the FBXL family (Fig. 1A) and FBXO and
FBXW families (data not shown) in a murine lung epithelial (MLE)
cell line. Effectiveness of V5 tagged F-box protein expression was an-
alyzed by immunoblotting (Fig. 1A, upper blot). CaMKI protein was
most efﬁciently degraded by Fbxl12, a protein upregulated during
TGF-β-induced G1 arrest [4]. Fbxl12 plasmid effects were selective,
as its expression did not alter immunoreactive PKCα or p38α/β levels
(Fig. 1A). Transfection with increasing amounts of Fbxl12 plasmid was
sufﬁcient to mediate degradation of CaMKI in a dose-dependent
manner unlike CaMKII (Fig. 1B). To evaluate if CaMKI degradation
might cause G1 arrest we overexpressed Fbxl12 and LacZ plasmids
in cells labeled with BrdU and performed analysis by 2-color ﬂow
cytometry (Fig. 1C). Expression of Fbxl12 plasmid, unlike control plas-
mid, increased the relative proportion of cells within the G1 phase
(Fig. 1C). These effects were not associated with increased cellular ap-
optosis (data not shown). We next examined cyclin D1/cdk4 complex
formation in the cells after Fbxl12 plasmid expression. Here, immuno-
precipitation using cdk4 antibodies followed by cyclin D1 immuno-
blotting revealed a signiﬁcant loss of cyclin D1 in the complex after
Fbxl12 plasmid expression (Fig. 1D). This effect was recapitulated
using CaMKI shRNA where CaMKI depletion in cells signiﬁcantly
decreased levels of immunoreactive cdk4 in the complex compared
to cells expressing control shRNA (Fig. 1E). These results suggest
that elimination of CaMKI by Fbxl12 mediated degradation or CaMKI
knockdown induces G1 arrest via impaired assembly of the cyclin
D1/cdk4 complex in lung epithelia. In addition, several treatments
that are known as G1 arrest inducers [37–40] up-regulated FBXL12
which was correlated with signiﬁcant loss of CaMKI expression
(Fig. 1F).
3.2. Fbxl12 binds CaMKI directly to trigger its degradation
We next examined CaMKI half-life after Fbxl12 overexpression
(Fig. 2A) and knockdown (Fig. 2B). Overexpression of Fbxl12 plasmid
compared to control plasmid signiﬁcantly decreased CaMKI half-life
(Fig. 2A), whereas knockdown of Fbxl12 using siRNA increased CaMKI
lifespan (Fig. 2B). MG132, a proteasomal inhibitor, stabilized CaMKI
levels unlike leupeptin, a lysosomal inhibitor (Fig. 2C). Endogenous
Fbxl12 and CaMKI interacted as demonstrated after Fbxl12 immuno-
precipitation followed by immunoblot analysis with CaMKI antibodies
using lysates of cells exposed to Ca2+ or lipopolysaccharide (LPS), or
cells transfected with CaMKI plasmid (Fig. 2D). Indeed, Ca2+ decreased
binding between CaMKI and Fbxl12 whereas LPS, that blocks cell pro-
liferation causing G1 arrest [41,42], induced CaMKI-Fbxl12 associa-
tion (Fig. 2D). Further, ectopic expression of control plasmid, LacZ, or
V5-Fbxl12 plasmid followed by pull down assays using V5-beads
showed that CaMKI and Fbxl12 were bound consistent with results
obtained by co-immunoprecipitation (Fig. 2E). Thus, both endogenous
and ectopically expressed FBXL2 interact with CaMKI. Last, Fbxl12 and
CaMKI co-localized in the cytoplasm of MLE cells under unstimulated
conditions and after Ca2+ or LPS exposure (Fig. 2F).
3.3. Fbxl12 targets CaMKI for ubiquitination
To demonstrate that CaMKI is ubiquitinated we performed immu-
noprecipitation using CaMKI antibodies (Fig. 3A) followed by immu-
noblotting with anti-ubiquitin antibodies (Fig. 3A). To support these
observation we also used immunoprecipitation with V5 antibodies
in the cells co-expressed V5-CaMKI and HA-ubiquitin (Fig. 3B).
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F-box proteins belonging to the L family. The cells were lysed and analyzed by immunoblotting using V5, CaMKI, PKCα, p38α/β and β-actin antibodies. (B) MLE cells transfected
with increasing amounts of Fbxl12 plasmid were analyzed by immunoblotting with CaMKI, CaMKII, V5 and β-actin antibodies. (C) Flow cytometric analysis of the cells
transfectedwith LacZ and Fbxl12 plasmids. (D)MLE cells transfectedwith control plasmid LacZ and Fbxl12 plasmidwere processed for immunoprecipitation using cdk4 antibody.
The cdk4/cyclin D1 complex was then analyzed by immunoblotting using cyclin D1 antibody. (E) MLE cells were transfected with control shRNA and CaMKI shRNA. Cells were
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SCFFbxl12 with addition of ubiquitin, E1, and E2 enzymes revealed
that the reactions generated polyubiquitinated\ CaMKI (Fig. 3C).
To identify the ubiquitination acceptor site(s) within CaMKI, we
constructed V5-tagged carboxyl-terminal deletion mutants, expressed
the plasmids in MLE cells before exposure to MG132 and analysis by
V5 immunoblotting (Fig. 3D,E). F-boxproteins are the receptors that usu-
ally recruit phosphorylated substrates targeting their phosphodegrons.
CaMKI is activated via binding to CaM and following phosphorylation
at Thr177. In addition, the CaMKI294/296 truncated mutants unlike the
other downstream mutants lacking CaM-binding site are the only mu-
tants that can stay active and phosphorylated at Thr177 without binding
to CaM [43]. Thus, we designed the C-terminal truncation mutants that
allowed the Fbxl12 binds CaMKI to identify potential ubiquitination
site within this kinase. The appearance of polyubiquitinated CaMKI
full-length (FL) and other polyubiquitinated constructs (CaMKI181,
CaMKI271, CaMKI296) suggested that the ubiquitination acceptor site
may be localized within a NH2-terminal region of the kinase upstream
of its phosphodegron that encompass residues Pro171 to Thr181
(Fig. 3E). Expression of point mutations at candidate lysines within the
NH2-terminal region of CaMKI in cells suggested that Lys59 might be a
putative ubiquitination site for CaMKI (Fig. 3F,G). This CaMKI variant
exhibited a signiﬁcantly extended half-life compared to CaMKI FL
(Fig. 3H,I). The co-expression of Fbxl12 plasmid with either CaMKI FLor CaMKI K59R plasmids led to degradation of CaMKI FL, but not
the CaMKI K59R mutant (Fig. 3J). Thus, CaMKI appears to be
polyubiquitinated at K59 and degraded via the proteosomal path-
way in lung epithelium.
3.4. CaMKI controls cell cycle progression in lung epithelia via regulation
of phosphorylation and subcellular localization of p27
Mitogen-activated Ca2+ inﬂux from the extracellular medium is a
key stimulus that regulates cell proliferation via rapid activation
CaM-dependent kinases [9,44–47]. To evaluate the role of CaMKI in
G1 progression and assembly of the cyclin D1/cdk4 complex by p27,
we ﬁrst transfected A549 cells (Fig. 4B) or MLE cells (data not shown)
with LacZ, CaMKI or Fbxl12 plasmids. Cells were then synchronized to
G0 by serum depletion for 48 h and released by addition of 10%
serum. The percent of S phase at all time-points analyzed by ﬂow cy-
tometry is indicated at the top of panels Fig. 4A–C. The levels of signal-
ing proteinswere then analyzed by immunoblotting. Overexpression of
CaMKI plasmid prolonged cell cycle progression evidenced by accelera-
tion of the transition from G0 to the S phase, accumulation of S-phase
population and robust time-dependent expression of cdk4, cyclin D1
and p27 levels in MLE and A549 cells during 24 h of analysis (Fig. 4B).
By comparison, Fbxl12 plasmid expression induced degradation of
CaMKI, reduced cyclin D1 levels, and increased late phase p27
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ylation of p27 at S10 that is necessary for its nuclear export at G0/G1
followed by its phosphorylation at Thr157 and Thr198 in human
cells regulates assembly of cyclin D1/cdk4 at early G1 [28,29].
p27 phosphorylation levels in control cells (LacZ) and cells over-
expressing CaMKI plasmid were correlated with CaMKI activation
during cell cycle progression (Fig. 4A–B). After exposing cells
to FBS the maximum phosphorylation of p27 at Thr157 and
Thr198 in control cells was detected at 6–12 h (Fig. 4A) whereas
CaMKI overexpression stabilized its phosphorylation from 2 to 12 h
(Fig. 4B). Overexpression of Fbxl12 plasmid totally abrogated p27
phosphorylation at Thr157 and Thr198 in further support that
CaMKI might be involved in p27 phosphorylation (Fig. 4C). The
levels of Fbxl12 increased in a time-dependent manner in control
cells which generally correlated with down-regulation of CaMKI
(Fig. 4A). Interestingly, overexpression of CaMKI plasmid signiﬁcantly
decreased Fbxl12 levels (Fig. 4B) reﬂecting an inverse relationship be-
tween these proteins during cell cycle progression. Formation of the
cdk4/cyclinD1/p27 complex increases during early G1 [29]. Consistent
with this our results show increasing expression of these proteins
during this time frame in control and CaMKI overexpressing cells
(Fig. 4A–B). Moreover, Fbxl12 overexpression induced G1 arrest in
these cells and could impair cdk4/cyclinD1/p27 complex assembly via
abrogation of Thr157 and Thr198 phosphorylation (Fig. 4C).To assess subcellular localization of endogenous p27 in lung epi-
thelia LacZ, CaMKI and Fbxl12 plasmids were expressed in cells as
was described above. Localization of endogenous p27 and p-CaMKI
were analyzed over time (0–24 h) (Fig. 4D–G). Localization of
phosphorylated CaMKI (p-CaMKI) in the control cells and cells
overexpressing CaMKI did not change at indicated times, whereas
the expression of CaMKI was very weak in the cells overexpressing
Fbxl12 (Fig. 4D–G). Localization of p27 in control cells was nuclear
at G0 and then translocated to cytoplasm, whereas p27 in the cells
with overexpressing CaMKI was distributed between the cytoplasm
and the nucleus at Go and then at later time points was mostly cyto-
plasmic. However, in the Fbxl12-expressing cells p27 was predomi-
nantly mislocalized in the nucleus at most time points. Thus, these
data suggest that CaMKI might also regulate p27 subcellular localiza-
tion in lung epithelia. These observations were conﬁrmed by addi-
tional experiments after transfection of Myc-, Flag- or GFP-tagged
p27 in cells (Figs. 6–8).
3.5. CaMKI regulates assembly of cyclin D1/cdk4 via association with p27
We ﬁrst performed the pull down of p27 from A549 cells
overexpressing LacZ, CaMKI or Fbxl12 plasmid using CaMKI-
conjugated beads. The binding was monitored by immunoblotting
(Fig. 5A–C). Here, we observed time-dependent association of
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that overexpression of CaMKI accelerates and extends the time of
CaMKI-p27 association that also correlates with p27 phosphoryla-
tion levels (Fig. 5B). However, Fbxl12 overexpression signiﬁcantly
abrogates the level of p27 associated with CaMKI and phosphoryla-
tion (Fig. 5C). Immunoprecipitation assays also supported these
observations (data not shown). The association of p27 and CaMKI was
also conﬁrmed by pull down assays using the puriﬁed recombinant pro-
tein p27 and CaMKI-conjugated beads (Fig. 5D). These studies show
that KN-93, a CaMKI inhibitor signiﬁcantly abrogated p27-CaMKI in-
teraction (Fig. 5D). Other pull down assays performed with CaMKI-
conjugated beads using lysates from MLE cells exposed to KN-93 or
Ca2+ also demonstrated that the inhibitor signiﬁcantly abrogated bind-
ing of CaMKI to p27 (Fig. 5E). The pull downof CaMKI from LacZ-, CaMK-
or Fbxl12-transfected cells using p27-conjugated beads also revealed
that the expression of Fbxl12 reduced the level of CaMKI associated
with the beads (Fig. 5F). Immunoprecipitation from these cells using
cdk4 antibody (Fig. 5G–I) followed by immunoblot analysis with p27
and cyclin D1 antibodies demonstrated that CaMKI compared to Lac Z
plasmid expression induced cdk4/cyclin D1/p27 complex formation at
all indicated times compared to control (Fig. 5G,H). Overexpression ofFbxl12 plasmid greatly reduced cyclin D1 detected within the complex
(Fig. 5I). The binding was monitored at the time when p27 was maxi-
mally co-localized with CaMKI as was previously shown (Fig. 4).
3.6. CaMKI phosphorylates p27 regulating its subcellular localization in
human lung epithelia
To test our hypothesis that CaMKI phosphorylates p27 at Thr157
and Thr198 we ﬁrst made a sequence alignment of the CaMKI recogni-
tion consensus site with sequences within p27 that included Thr157
and Thr198. Sequence alignment demonstrates that the motif is
noncanonical but partially resembles a CaMKI consensus sequence
(Figs. 6A, S1A). We then performed in vitro reactions using p27 an ac-
tive or inactive forms of CaMKI with Ca2+. Immunoblot analysis
using phospho-speciﬁc p27 Thr157 and p27 Thr198 antibody revealed
that only an active form of CaMKI was able to robustly phosphorylate
p27 in vitro (Fig. 6B). To support this observation A549 cells were
transfected with plasmids encoding Myc-tagged p27 wild-type (WT)
or two point mutants, Myc-p27T157A and Myc-p27T198A followed by
pull down with anti-Myc agarose. The Myc-conjugated p27 WT and
p27 mutants were then dephosphorylated with alkaline phosphatase
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Fig. 4. CaMKI controls cell cycle progression in lung epithelia via p27 phosphorylation and its subcellular localization. A549 cells were transfected with LacZ (A), CaMKI (B) or Fbxl12
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Ca2+ and CaM (Fig. 6C). The results reveal that mutations of both
sites reduced p27 phosphorylation with the p27T198A mutation
exhibiting signiﬁcantly lower levels of phosphorylation (Fig. 6C).
To test if the phosphorylation at T157 and T198 would affect
cdk4/cyclinD1/p27 complex formation, A549 cells were co-transfected
with V5-CaMKI and either Myc-p27WT, Myc-p27T157A, or Myc-
p27T198A plasmids followed by V5 immunoprecipitation (Fig. 6D).
Here, expression of both p27 mutants reduced complex formation
evidenced by loss of cdk4 and cyclin D1 (Fig. 6D). A549 cells
co-transfected as described above were also starved and then released
with FBS followed by immunostaining (Fig. 6E–G). The results show
that serum addition and overexpression of CaMKI had no effect on the
subcellular localization of mutants. Both p27 T157A and p27 T198A
mutants were predominantly nuclear at indicated time points, whereas
the p27WT protein translocated to the cytoplasm in response to serum
addition or CaMKI overexpression (Fig. 6E–G). Localization of endoge-
nous p27 phosphorylated at T157 (Fig. S2A–D) and T198 (Fig. S3A–D)
in A549 cells transfected with LacZ, CaMKI or Fbxl12 plasmids in re-
sponse to serum was also visualized by immunostaining. The results
conﬁrm our ﬁndings revealing CaMKI-dependent localization of mu-
tants in the cells. Thus, CaMKI triggers p27 phosphorylation at T157
and T198 sites that stabilize the cdk4/cyclinD1/p27 complex and regu-
late p27 intracellular localization in human lung epithelia.3.7. CaMKI phosphorylates p27 regulating its subcellular localization in
mouse lung epithelia
By sequence alignment, T157 is absent in mouse p27, whereas
T198 in human sequence is corresponding to T197 in mouse p27
(Fig. S1A–C). To verify if CaMKI can phosphorylate p27 puriﬁed
from mouse cells we performed in vitro phosphorylation reactions
as above (Fig. 7A). Only an active form of CaMKI was able to phos-
phorylate p27. Thus, CaMKI phosphorylates human and mouse p27.
Analysis of the mouse p27 sequence reveals two non-canonical motifs
with partial resemblance to a CaMKI consensus recognition signature
(Fig. 7B). T170 and T197 are phosphorylated by AMPK [48,49]. These
phosphorylation sites regulate p27 cellular localization [48,49]. To in-
vestigate if CaMKI can phosphorylate mouse p27 at these two sites,
MLE cells were transfected with p27 WT, p27 T170A, p27 T197A,
or p27 T170A/T197A-Flag-tagged mutant plasmids followed by pull
down with Flag-agarose. Agarose beads conjugated to Flag-p27WT,
Flag-p27T170A, Flag-p27T197A and Flag-p27T170A/T197A were then
dephosphorylated with alkaline phosphatase and used in phosphory-
lation reactions with CaMKI in the presence of [γ-32P]-ATP, Ca2+ and
CaM. The results show that mutations of both sites signiﬁcantly
reduced p27 phosphorylation, whereas the double mutant exhibited
total loss of ability to be phosphorylated by CaMKI (Fig. 7C).
Co-expression of His-CaMKI plasmid with either Flag-tagged p27 WT
p27T157
p27T198
p27S10
p27
CaMKI: + + + + + +
FBS:0 2 4 6 12 24 beads
p27T157
p27T198
p27S10
p27
Fbxl12: + + + + + +
FBS:0 2 4 6 12 24 beads
p27T198
p27S10
p27
LacZ:+ + + + + +
FBS:0 2 4 6 12 24 beads
p27T157
A B C
Ca2+: +
KN-93: + p2
7
Ca
M
KI
be
ad
s
p27
p27PD
C KN
-9
3
Ca
2+
be
ad
s
Ca
M
KI
p27Input
La
cZ
Ca
M
KI
Fb
xl
12
CaMKI
be
ad
s
p2
7
CaMKI
PD
Input
H I
Ig
G
In
p 0 2 4 6 h (FBS)IP:cdk4
p27
cyclinD1
Ig
G
In
p 0 2 4 6 h (FBS)IP:cdk4
p27
cyclinD1
Ig
G
In
p 0 2 4 6 h (FBS)IP:cdk4
p27
cyclinD1
LacZ: + + + + + + CaMKI: + + + + + + Fbxl12: + + + + + +
G
cdk4 cdk4 cdk4
CaMKI CaMKI CaMKI
D E F
--
- -
Fig. 5. CaMKI binds p27 and regulates cdk4/cyclinD1/p27 complex formation. CaMKI binds p27. (A–C) A549 cells transfected with LacZ (A), CaMKI (B) and Fbxl12 (C) were starved
for 48 h and then recovered with addition of 10% FBS. Cells were then collected and processed for pull down assays using CaMKI-conjugated beads followed by immunoblotting
with appropriate antibodies. (D) Direct binding between CaMKI and p27. Puriﬁed recombinant p27 was pre-incubated with CaMKI beads with or without Ca2+ or KN-93 as
indicated on top of the lanes, followed by immunoblot analysis with p27 antibody. (E) Cells exposed to KN-93 (20 μM) or Ca2+(2 mM) for 1 h were then collected followed by
pull down assays using CaMKI-conjugated beads. (F) Cells transfected as described above (A–C) were processed for pull down assays using beads conjugated to p27 followed by
immunoblot analysis with CaMKI antibody. (G–I) CaMKI regulates cdk4/cyclinD1/p27 complex formation. Cells transfected with LacZ (G), CaMKI (H) or Fbxl12 plasmids (I) were
released with 10% FBS addition and then collected at indicated times for immunoprecipitation using cdk4 antibody. Immunoprecipitants and input were analyzed by immunoblotting
using p27 and cyclin D1 antibodies. n = 2 experiments.
2054 R.K. Mallampalli et al. / Cellular Signalling 25 (2013) 2047–2059or various p27 mutant plasmids followed by pull down assays using
His-conjugated beads revealed signiﬁcantly decreased binding of
p27 mutants with CaMKI in contrast to p27 WT (Fig. 7D).
To investigate if phosphorylation of p27 at T170 and T197 sites
by CaMKI can regulate its intracellular localization, MLE cells were
co-transfected with CaMKI plasmid and either Flag-tagged p27 WT
or p27 mutant plasmids as described above. Cells were then starved
and ﬁnally released with serum addition followed by immunostaining
at indicated times (Fig. 7E–G). The results demonstrate that both
p27T170A and p27T197A mutants were nuclear whereas p27 WT
translocated to the cytoplasm in response to serum and CaMKI
overexpression (Fig. 7E–G). Thus, CaMKI might regulate p27 intracel-
lular localization in mouse lung epithelia via phosphorylation of this
protein at T170 and T197 sites.
3.8. Crosstalk between CaMKI and AKT on p27 phosphorylation
CaMKI and AKT are phosphorylated by upstream activators, and
CaMKK becomes active after elevation of Ca2+ within minutes [50].
Serum addition to quiescent cells immediately (3–20 s.) induces inﬂux
of extracellular Ca2+ [50]. CaMKI, a primary substrate of CaMKK, can be
activated in less than 5 min, whereas PKB/AKT, is a secondary substrate
because its activation by CaMKK is slow (~1 h) [51]. To evaluate the
possible relationship between CaMKI and AKT on p27 phosphorylation
during the cell cycle, we ﬁrst analyzed time-dependent activation ofCaMKI, AKT, and p27 during cell cycle progression. Immunoblot analysis
demonstrated maximal expression of CaMKI within the ﬁrst 30 min
after serum addition whereas AKT was stably expressed at all indicated
time points in MLE cells (Fig. 8A). The activated form of CaMKI was
detected in 5 min after serum addition and remained active at all indi-
cated time points with variations between 5 min to 6 h. However, AKT
activation at both sites (S473 and T308) that are necessary to confer its
fully activated form was time dependent. Phosphorylation of p27 at
T157 increased from 15 min to 6 h whereas phosphorylation at T198
was detected later after release from G0 (Fig. 8A). Total levels of p27
were maximal from 1 to 6 h. Formation of p27-cyclin D1/cdk4 com-
plexes and p27 phosphorylation at T157 and T198 increased during
early G1 from 2 to 6 h as shown above (Figs. 4, 6) and temporally was
linked to activation of CaMKI and AKT (Fig. 8A). Thus, both kinases
can phosphorylate p27 at these sites (T157 and T198) and induce
cyclin D1/cdk4 complex formation. However the active form of CaMKI
appeared prior to AKT activation. Thus, to evaluate which kinase is
upstream to phosphorylate p27 we exposed MLE cells to the CaMKK
inhibitor, STO-609, the CaMKI inhibitor, KN-93 or LY294002, a known
AKT inhibitor (Fig. 8B–E). The results show that both kinases are sensi-
tive to these inhibitors. These observations suggest that CaMKI and AKT
actions might be modulated by Ca2+. To test this hypothesis we ex-
posed cells to the Ca2+ chelator, EGTA, and then immunoprecipitated
CaMKI and AKT using p27 antibodies. Immunoblot analysis demon-
strated that binding of CaMKI and AKT to p27 and its phosphorylation
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Overexpression of CaMKI or AKT in A549 cells shows that FBS-induced
p27 phosphorylation correlates with CaMKI and AKT activation
(Fig. S4A,B). However, phosphorylation of p27 by AKT exhibited a
slight delay compared to phosphorylation by CaMKI (Fig. S4A,B).
In addition, overexpression of Fbxl12 in the cells regulated AKT
intracellular localization by induction of its nuclear translocation
(Fig. S4C). Finally, GFP-p27 plasmid was transfected or co-transfected
with CaMKI plasmid into MLE cells followed by starvation for 48 h.
Cells were then pulsed with 10% FBS or Ca2+ and ﬁxed at indicated
times followed by immunostaining (Fig. 8F,G). The results show that
both treatments induced time-dependent p27 cytoplasmic transloca-
tion in a similar manner. Immunoblot analysis demonstrated compara-
ble activation of CaMKI and AKT by these agents with a little delay in
activation of AKT (Fig. 8H,I). Thus, these data are compatible with the
idea that CaMKI pathway is upstream of AKT and that CaMKI might be
a prime activator of p27.
4. Discussion
The CaMK family of serine/threonine kinases plays an essential role
in cell cycle progression [11]. The molecular regulation of CaMKI, a keymember of this family that controls G1 progression through regulation
of cyclin D1/cdk4 complexes [18], is poorly characterized at the level of
protein stability. These studies are the ﬁrst demonstration of CaMKI
degradation by the proteosomal pathway mediated by the F box
protein, Fbxl12. CaMKI was shown to be a direct substrate for Fbxl12
and modulation of this SCF component altered cell cycle progression
and cyclin D1/cdk4 complex assembly through CaMKI abundance.
Moreover, our studies support a mechanism by which Fbxl12 via
CaMKI degradation mediates G1 arrest. Here, CaMKI regulates cyclin
D1/cdk4 complex formation by triggering phosphorylation of p27,
which mediates assembly, activation and cytoplasmic localization of
cyclin D-cdk [17,52,53]. As a whole, these observations suggest that
critical a SCF component (Fbxl12) acting through CaMKI may control
cell fate and replicative capacity.
Here, we provide evidence that p27 is a potential substrate for
CaMKI. Phosphorylation of p27 at Thr157 and Thr198 sites stabilizes
the cyclin D1/cdk4 complex and regulates its activation during G1
[28,29,54]. In quiescent cells p27 is localized in the nucleus but
following mitogen-stimulated nuclear export in early G1, p27 is
needed to promote cyclin D1/cdk4 assembly. For its cytoplasmic
retention p27 is phosphorylated at serine 10 that facilitates binding
to exportin 1 required for p27 cytoplasmic translocation and G1
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through concerted actions of a number of kinases and cytoplasmic
retention is affected by the molecular chaperone 14-3-3 [23,28,56].
For example, p27 phosphorylation at T157and T198 in the cytoplasm
is mediated by AKT that also inﬂuences G1 progression [57–59].
However, a number of studies demonstrate that mitogen-induced
Ca2+ elevations in cells trigger rapid activation of the CaMK cascade
[44,60–62]. CaMKI is required for G1 progression via regulation of
cyclin D1/cdk4 complexes, but how this kinase controls assembly of
these proteins is unknown. Our results demonstrate that CaMKI was
rapidly activated by serum and its activation correlated with p27
phosphorylation at Thr157 and Thr198 in human lung epithelia
(Figs. 4A, 8A). Overexpression of CaMKI accelerated and prolonged
p27 phosphorylation, whereas degradation of CaMKI mediated by
Fbxl12 dramatically reduced p27 phosphorylation at these molecular
sites (Fig. 4B,C). These observations were also conﬁrmed by investiga-
tion of p27 intracellular localization during cell cycle progression
(Fig. 4D–G). We demonstrate that overexpression of CaMKI acceler-
ated the formation of cyclin D1/cdk4 complexes, whereas this assem-
bly was reduced via Fbxl12-induced CaMKI degradation (Figs. 1D,E;
5G,I). In vitro phosphorylation assays showed that CaMKI phosphory-
lates p27 at Thr157 and Thr198 in human cells (Fig. 6B,C); an effect
reduced using p27 Thr157 and Thr198 point mutants. Further,phosphorylation of human p27 at these sites regulated its intracellu-
lar localization (Figs. 6E–G, S2–S3). Collectively, these results suggest
that CaMKI is involved in mediating G1 progression by promoting
cyclin D1/cdk4 complex formation through site-speciﬁc p27 phos-
phorylation in human lung epithelia.
The p27 NLS that includes a stretch between 151 and 163 residues
can regulate p27 intracellular localization via phosphorylation of
residues within or juxtaposed near an NLS [63]. For example, AMP-
activated protein kinase (AMPK) can phosphorylate p27 at T170
located close to the p27 NLS and control its cellular localization [48].
AMPK-mediated phosphorylation of p27 at T197 induces binding to
14-3-3 and increases its stability in a murine Tsc2-null tumor cell
line [49]. Indeed, T170 and T197 are attractive sites for CaMKI that
have some similarities to a consensus phosphorylation sequence rec-
ognized by CaMKI (Fig. 7B). Our studies demonstrate that CaMKI
phosphorylates Thr170 and Thr197 within murine p27 to regulate
its subcellular localization in mouse lung epithelia (Fig. 7). Thus, the
data suggest that CaMKI might be a regulator of G1 progression in
mouse lung epithelia via phosphorylation of p27. We also believe
that CaMKI can phosphorylate Thr170 within human p27.
Since, AKT regulates G1 progression in cells its raises the possibil-
ity of crosstalk between AKT and CaMKI induced p27 phosphoryla-
tion. The immediate Ca2+ inﬂux that occurs in response to mitogen
STO 609: 0 1 2 3 4 h STO 609: 0 1 2 3 5 10 μg/ml
AKT
p AKT(S473)
p CaMKI
β actin
CaMKI
CaMKI
p CaMKI
p AKT(S473)
AKT
β actin
LY294002: 0 1 2 4 6 h
p CaMKI
KN 93: 0 20 50 μM
p AKT(S473)
β actin
CaMKI
AKT
AKT
p AKT(S473)
p CaMKI
β actin
CaMKI
β actin
p CaMKI
p AKT
CaMKI
AKT
FBS: 0 15’ 30’ 1 2 4 h
(S473)
Ca2+: 0 15’ 30’ 1 2 4 h
A B C
D E
F G H IDAPI GFP p27 Merge
C
FB
S 
(3h
)
FB
S 
(6h
)
Ca
M
KI
DAPI GFP p27 Merge
C
Ca
2+
(3h
)
Ca
2+
(6h
)
EG
TA
FBS: 0 5’15’30’1 2 3 4 6 12 18 24 h
p27T157
p27T198
p27
p CaMKI
CaMKI
p AKT(S473)
p AKT(T308)
AKT
cdk4
cyclin D1
β actin
Fig. 8. Coordinate regulation of CaMKI and AKT activities via Ca2+ and serum control p27 localization in lung epithelia. (A) A549 cells were synchronized by serum starvation for
48 h. After 10% FBS addition cells were collected at indicated times and processed for immunoblotting for proteins of interest. (B, C) MLE cells were exposed to the CaMKK inhibitor,
STO-609 (10 μg/ml) at various times (B) and concentrations (C, 2 h). (D, E) Cells were also exposed to the AKT inhibitor, LY294002 (30 μM) at various time (D) or CaMKI inhibitor,
KN-93 for 1 h (E) and then analyzed by immunoblotting using antibodies against CaMKI, AKT, and phosphorylation forms. (F, G) MLE cells transfected with GFP-p27 were starved
by serum depletion for 48 h and then exposed to 10% FBS (A) or 2 mM Ca2+ (B) followed by ﬁxation at indicated times and immunostaining. Some of these cells were pre-incubated
with EGTA as described above or co-transfected with CaMKI plasmid. DAPI was used for visualization of nuclei. Scale bar, 10 μm. (H, I) MLE cells were synchronized by starvation for
48 h and then exposed to 10% FBS (H) or 2 mM Ca2+ (I) for indicated times. Cells were then harvested and analyzed by immunoblotting with CaMKI and AKT antibodies (data are
from n = 3 experiments).
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early G1 phase leads to reduction in cellular proliferation [44]. External
Ca2+ inﬂux through the Ca2+ channels is important and sufﬁcient for
cell cycle progression that leads to activation of critical signaling events
upstream of CaMKs [60,61,64]. The Ca2+ channel blocker, amlodipine
stimulates G1 arrest and growth inhibition via reduction of cyclin D1
and cdk4 protein levels, inhibition of cdk/cyclin-associated kinase activ-
ities, reduction of pRb and induction of p21(Waf1/Cip) expression [65].
Expression of Ca2+ channels depends on the stage of the cell cycle but it
is usually higher during G1 [45]. Thus, Ca2+ is an essential mitogenic
stimulus. Our studies show that Ca2+ is involved in p27 intracellular
localization and is sufﬁcient to activate CaMKI and AKT comparable to
serum stimulation (Fig. 8F–I). The Ca2+ signaling system triggers the
cell cycle through activation of the Ca2+/CaM-dependent protein kinase
cascade to catalyze critical phosphorylation events [66–69]. Binding of
Ca2+/CaM to CaMKI exposes its activation loop site to allow phosphor-
ylation by the upstream CaMKK that becomes active within a minutes
after mitogen exposure; concomitantly, Ca2+/CaM engagement to
CaMKI also activates secondary targets such as AKT [51] and AMPK
[70–73]. This was reﬂected in our experiments where AKT activation
exhibited a slight delay in comparison to CaMKI activation (Figs. 8A,H,I; S4A,B). CaMKI and AKT are multifunctional kinases involved in
many cellular signaling pathways that are seldom linear and often
form complex networks with other signaling pathways. This crosstalk
can occur at several levels; indeed there can be direct phosphorylation
between protein kinases or regulatory phosphorylation of either an up-
stream or downstream effectors. Thus, crosstalk between the CaMKI
and PKB/AKT signaling pathwaysmay reﬂect a very important commu-
nication network. In spite of p27 phosphorylation at T157 and T198 as
candidate sites for both kinases the activation of CaMKI occurs earlier
than AKT (Fig. 8A,H). It was recently demonstrated that serum addition
immediately causes transient nuclear localization of AKT [28]. Because
phosphorylation of p27 at Thr157 is a cytoplasmic event, the authors
speculate that p27 requires another cytosolic factor that acts in concert
with AKT [28]. CaMKI is a predominantly cytosolic protein. Thus, based
on our results, CaMKI might be an upstream kinase that primes p27
for subsequent phosphorylation by AKT. It is also possible that these
two kinases can be regulated via different upstreampathways by differ-
ent hormones or growth factors included in serum. In addition, the
CaMKI cascade might also participate in cross talk with other signaling
pathways; CaMKK/CaMKI might activate the AMP-activated protein
kinase pathway, the mitogen-activated protein kinase pathway, or the
2058 R.K. Mallampalli et al. / Cellular Signalling 25 (2013) 2047–2059c-AMP-dependent protein kinase [74]. However, more research is
required to determine how these pathways act and are coordinately
regulated.
In conclusion, our report is the ﬁrst discover that an ubiquitin E3
ligase component, F‐box protein Fbxl12, mediates CaMKI degradation
via a proteasome‐directed pathway. These studies also reveal a new
CaMKI substrate, p27Kip1.Wehavedemonstrated that CaMKI phosphor-
ylates p27 at speciﬁc sites Thr157 and Thr198 in human cells and at
Thr170 and Thr197 in mouse cells which is critical for cdk4/cyclin D1
complex formation and p27 intracellular localization. This is the ﬁrst
description uncovering a mechanistic pathway whereby CaMKI partici-
pates in cdk4/cyclin D1 complex during G1 progression. Lastly, the acti-
vation of CaMKI during G1 transition followed by p27 phosphorylation
appears to be upstream to p27 phosphorylation by other kinases. Thus,
our report unveils the following novel discoveries regarding a relatively
new F‐box protein, Fbxl12, an E3 ligase component and how it controls
availability of the new substrate, CaMKI, which impacts cell cycle
progression. We also believe that these studies provide a signiﬁcant
conceptual andmechanistic advance in the understanding of themolec-
ular physiology related to cell cycle processes and might be used for
mechanism-based therapy.
Supplementary data to this article can be found online at http://
dx.doi.org/10.1016/j.cellsig.2013.05.012.
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